Ekaterina S. Frolova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekaterina S. Frolova has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Nadezhda G. Veselovskaya
Altai State Medical University
4 shared publications - Анна Владимировна Отт
Altai Regional Cardiology Dispensary; Altai State Medical University
3 shared publications - Galina A. Chumakova
Altai State Medical University
2 shared publications - Anastasia V. Maslova1 shared publication
- Elena Trubina
Altai Regional Cardiology Dispensary
1 shared publication - L. V. Barinova
Altai Regional Cardiology Dispensary
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (8S) , 7013
Restrictive cardiomyopathy: difficulties in diagnosis and management. A case report
Intr oduction . Despite recent advances in the diagnosis and treatment of various cardiomyopathies (CMP), the diagnosis of restrictive cardiomyopathy (RCM) remains the most challenging due to the heterogeneity of etiologic factors and the lack of timely interpretation of echocardiographic criteria for myocardial restriction. The association of RCM with the most common cardiovascular diseases further complicates its diagnosis. At the same time, the prognosis for patients with RCM, especially those with a genetic basis, is significantly worse than for other forms of cardiomyopathy. Brief description. This article presents a case of a 47-year-old female patient diagnosed with myocardial infarction complicated by heart failure (HF) refractory to cardiotropic therapy. Delayed assessment of cardiac anatomical parameters (atrial dilation with small ventricular sizes), the type of left ventricular diastolic dysfunction, and the characteristics of myocardial longitudinal strain abnormalities led to a late RCM diagnosis, imitating HF secondary to myocardial infarction. Identification of the genetic disease nature (a mutation in the genes encoding sarcomeric proteins) facilitated the selection of a curative treatment option — heart transplantation. Discussion . This clinical example highlights the need for a thorough approach to diagnosing various cardiomyopathy types using primary and secondary echocardiographic criteria, and, if necessary, genetic testing, especially in cases of refractory heart failure despite ongoing cardiotropic therapy.
- 13 August 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (8S) , 7013
Open AccessRestrictive cardiomyopathy: difficulties in diagnosis and management. A case report
Intr oduction . Despite recent advances in the diagnosis and treatment of various cardiomyopathies (CMP), the diagnosis of restrictive cardiomyopathy (RCM) remains the most challenging due to the heterogeneity of etiologic factors and the lack of timely interpretation of echocardiographic criteria for myocardial restriction. The association of RCM with the most common cardiovascular diseases further complicates its diagnosis. At the same time, the prognosis for patients with RCM, especially those with a genetic basis, is significantly worse than for other forms of cardiomyopathy. Brief description. This article presents a case of a 47-year-old female patient diagnosed with myocardial infarction complicated by heart failure (HF) refractory to cardiotropic therapy. Delayed assessment of cardiac anatomical parameters (atrial dilation with small ventricular sizes), the type of left ventricular diastolic dysfunction, and the characteristics of myocardial longitudinal strain abnormalities led to a late RCM diagnosis, imitating HF secondary to myocardial infarction. Identification of the genetic disease nature (a mutation in the genes encoding sarcomeric proteins) facilitated the selection of a curative treatment option — heart transplantation. Discussion . This clinical example highlights the need for a thorough approach to diagnosing various cardiomyopathy types using primary and secondary echocardiographic criteria, and, if necessary, genetic testing, especially in cases of refractory heart failure despite ongoing cardiotropic therapy.
- 16 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (1S)
Associated pulmonary arterial hypertension: difficulties in diagnosis and management. A case report
Introduction. Despite recent advances in the diagnosis and treatment of pulmonary arterial hypertension (PAH), including those associated with systemic connective tissue diseases (CTDs), late diagnosis persists in clinical practice. Newly diagnosed patients with PAH associated with CTDs experience significant functional and hemodynamic impairment and a high mortality risk. The prognosis for this category of patients is significantly worse than for other PAH types. PAH is a rare but severe complication of systemic lupus erythematosus, the exact etiopathogenesis of which remains unknown. Brief description . This article presents a case of a 54-year-old female patient diagnosed with coronary artery disease, coronary artery stenting, and a primary complaint of shortness of breath, which, in fact, masks the manifestation of CTDs. Echocardiography-based diagnosis of pulmonary hypertension was long interpreted as a manifestation of heart failure, despite the absence of left heart remodeling. Further examination confirmed systemic lupus erythematosus and associated pulmonary arterial hypertension (PAH), followed by the initiation of PAH-specific therapy with improved dynamics of the main risk criteria. Discussion. This case emphasizes the need for a thorough collection of complaints and medical history, not only related to obvious cardiovascular symptoms but also those of other systems and organs. In addition, a more detailed assessment of echocardiographic parameters with differential diagnosis of common causes of dyspnea from less common ones should be performed.
- 16 April 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (1S)
Associated pulmonary arterial hypertension: difficulties in diagnosis and management. A case report
Introduction. Despite recent advances in the diagnosis and treatment of pulmonary arterial hypertension (PAH), including those associated with systemic connective tissue diseases (CTDs), late diagnosis persists in clinical practice. Newly diagnosed patients with PAH associated with CTDs experience significant functional and hemodynamic impairment and a high mortality risk. The prognosis for this category of patients is significantly worse than for other PAH types. PAH is a rare but severe complication of systemic lupus erythematosus, the exact etiopathogenesis of which remains unknown. Brief description . This article presents a case of a 54-year-old female patient diagnosed with coronary artery disease, coronary artery stenting, and a primary complaint of shortness of breath, which, in fact, masks the manifestation of CTDs. Echocardiography-based diagnosis of pulmonary hypertension was long interpreted as a manifestation of heart failure, despite the absence of left heart remodeling. Further examination confirmed systemic lupus erythematosus and associated pulmonary arterial hypertension (PAH), followed by the initiation of PAH-specific therapy with improved dynamics of the main risk criteria. Discussion. This case emphasizes the need for a thorough collection of complaints and medical history, not only related to obvious cardiovascular symptoms but also those of other systems and organs. In addition, a more detailed assessment of echocardiographic parameters with differential diagnosis of common causes of dyspnea from less common ones should be performed.
- Open Access
- 1 January 2025
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 37 (3) , 55-59
PREDICTORS OF HOSPITAL COMPLICATIONS FOLLOWING AORTIC VALVE PROSTHESIS IN OBESE PATIENTS
Obesity is a global epidemic of the 21st century. Adipose tissue has pro-inflammatory and pro-fibrotic activity and leads to the development of endothelial dysfunction, resulting in cardiovascular disease (CVD). According to large international studies, obesity is a common comorbid condition in patients with aortic stenosis (AS). Surgical aortic valve replacement (SAVR) remains the «gold» standard for the treatment of patients with severe AS; however, obesity patients represent a group at increased risk of postoperative hospital postoperative complications. Therefore, an important area in modern cardiology is the study of risk factors (RF) for complications after SAVR in patients with obesity, with the development of an individualized preoperative preparation.
- 1 January 2025
- Published by Altay State Medical University in Bulletin of Medical Science
- Vol. 37 (3) , 55-59
Open AccessPREDICTORS OF HOSPITAL COMPLICATIONS FOLLOWING AORTIC VALVE PROSTHESIS IN OBESE PATIENTS
Obesity is a global epidemic of the 21st century. Adipose tissue has pro-inflammatory and pro-fibrotic activity and leads to the development of endothelial dysfunction, resulting in cardiovascular disease (CVD). According to large international studies, obesity is a common comorbid condition in patients with aortic stenosis (AS). Surgical aortic valve replacement (SAVR) remains the «gold» standard for the treatment of patients with severe AS; however, obesity patients represent a group at increased risk of postoperative hospital postoperative complications. Therefore, an important area in modern cardiology is the study of risk factors (RF) for complications after SAVR in patients with obesity, with the development of an individualized preoperative preparation.
- Open Access
- 15 December 2024
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 15 (4) , 344-353
COVID-19 and post-disease features in patients with obesity
The COVID-19 pandemic has affected the global population, causing significant economic effect, material damage, and irreparable human losses. Many countries were forced to promptly reorganize their healthcare system in order to save patients with COVID-19. The pathogenesis and specifics of the disease are not completely understood, but one pattern is particularly clear: COVID-19 tends to be more severe in people with obesity. Fatty tissue is known to support chronic low-grade inflammation and has its own endocrine activity. Over time, it became obvious that some patients still have consequences following the acute phase of COVID-19, which in some cases lead to irreversible changes in the body and reduced quality of life. This condition was called post-COVID syndrome. In this article, we review the long-term effects of COVID-19 on different body systems. We focused on pathogenic infection mechanisms and features of post-COVID syndrome in people with obesity.
- 15 December 2024
- Published by ECO-Vector LLC in Cardiosomatics
- Vol. 15 (4) , 344-353
Open AccessCOVID-19 and post-disease features in patients with obesity
The COVID-19 pandemic has affected the global population, causing significant economic effect, material damage, and irreparable human losses. Many countries were forced to promptly reorganize their healthcare system in order to save patients with COVID-19. The pathogenesis and specifics of the disease are not completely understood, but one pattern is particularly clear: COVID-19 tends to be more severe in people with obesity. Fatty tissue is known to support chronic low-grade inflammation and has its own endocrine activity. Over time, it became obvious that some patients still have consequences following the acute phase of COVID-19, which in some cases lead to irreversible changes in the body and reduced quality of life. This condition was called post-COVID syndrome. In this article, we review the long-term effects of COVID-19 on different body systems. We focused on pathogenic infection mechanisms and features of post-COVID syndrome in people with obesity.